Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women

Background Data on the predictive role of estimated glomerular filtration rate (eGFR) and osteoprotegerin (OPG) for cardiovascular (CVD) and all-cause mortality risk have been presented by our group and others. We now present data on the interactions between OPG with stage I to III chronic kidney disease (CKD) for all-cause and CVD mortality. Methods and Results The setting was a 15-year study of 1,292 women over 70 years of age initially randomized to a 5-year controlled trial of 1.2 g of calcium daily. Serum OPG and creatinine levels with complete mortality records obtained from the Western Australian Data Linkage System were available. Interactions were detected between OPG levels and eGFR for both CVD and all-cause mortality (P < 0.05). Compared to participants with eGFR ≥60ml/min/1.73m2 and low OPG, participants with eGFR of <60ml/min/1.73m2 and elevated OPG had a 61% and 75% increased risk of all-cause and CVD mortality respectively (multivariate-adjusted HR, 1.61; 95% CI, 1.27-2.05; P < 0.001 and HR, 1.75; 95% CI, 1.22-2.55; P = 0.003). This relationship with mortality was independent of decline in renal function (P<0.05). Specific causes of death in individuals with elevated OPG and stage III CKD highlighted an excess of coronary heart disease, renal failure and chronic obstructive pulmonary disease deaths (P < 0.05). Conclusion The association between elevated OPG levels with CVD and all-cause mortality was more evident in elderly women with poorer renal function. Assessment of OPG in the context of renal function may be important in studies investigating its relationship with all-cause and CVD mortality.

[1]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[2]  M. Sánchez-Niño,et al.  Osteoprotegerin and kidney disease , 2014, Journal of Nephrology.

[3]  K. Zhu,et al.  Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study , 2014, American Journal of Nephrology.

[4]  K. Zhu,et al.  Five-year decline in estimated glomerular filtration rate associated with a higher risk of renal disease and atherosclerotic vascular disease clinical events in elderly women. , 2013, QJM : monthly journal of the Association of Physicians.

[5]  K. Zhu,et al.  Estimated glomerular filtration rate as an independent predictor of atherosclerotic vascular disease in older women , 2012, BMC Nephrology.

[6]  W. März,et al.  Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J.,et al.  The New England Journal of Medicine , 2012 .

[8]  S. Aakhus,et al.  Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis , 2011, Journal of internal medicine.

[9]  K. Zhu,et al.  A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women , 2009, Clinical endocrinology.

[10]  B. Kestenbaum,et al.  Rapid decline of kidney function increases cardiovascular risk in the elderly. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  I. Jaussent,et al.  A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  E. Clark,et al.  Regulation of dendritic cell survival and cytokine production by osteoprotegerin , 2009, Journal of leukocyte biology.

[13]  A. Levin,et al.  Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  P. Bakke,et al.  Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.

[15]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[16]  F. Corallini,et al.  Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. , 2009, European journal of histochemistry : EJH.

[17]  A. J. Bass,et al.  A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. , 2008, Australian health review : a publication of the Australian Hospital Association.

[18]  M. Matsuhisa,et al.  Serum Osteoprotegerin as a Screening Tool for Coronary Artery Calcification Score in Diabetic Pre-Dialysis Patients , 2008, Hypertension Research.

[19]  I. Jaussent,et al.  Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[20]  J. Herlitz,et al.  Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. , 2008, Journal of the American College of Cardiology.

[21]  P. Kostenuik,et al.  Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice , 2008, Circulation.

[22]  A. Khera,et al.  Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). , 2007, The American journal of cardiology.

[23]  F. Islam,et al.  No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. , 2007, Bone.

[24]  S. Thiel,et al.  Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. , 2006, Journal of the American Society of Nephrology : JASN.

[25]  A. Lahiri,et al.  The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. , 2006, Journal of the American College of Cardiology.

[26]  Richard L Prince,et al.  Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. , 2006, Archives of internal medicine.

[27]  I. Jaussent,et al.  Plasma osteoprotegerin is associated with mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  P. Olesen,et al.  Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α , 2005, Diabetologia.

[29]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[30]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[31]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[32]  KatsuhitoMori,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002 .

[33]  Y. Ikari,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.

[34]  K. Godang,et al.  Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. , 2001, European journal of endocrinology.

[35]  T. Shigematsu,et al.  Osteoprotegerin levels before and after renal transplantation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  H Britt,et al.  ICPC PLUS© for Community Health? A Feasibility Study , 1997, Health information management : journal of the Health Information Management Association of Australia.

[37]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[38]  Brämer Gr International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.